Preclinical models suggest that combining BRAF and MEK inhibitors with PD-1 blockade therapy was of benefit to a subset of patients with BRAF(V600)-mutated metastatic melanoma [85]. This evidence concerns the gene MAP2K7 and metastatic melanoma.